IL-16- and other CD4 ligand-induced migration is dependent upon protein kinase C.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

IL-16- and other CD4 ligand-induced migration is dependent upon protein kinase C.

Cell Immunol. 1996 Feb 25;168(1):100-6. Unique Identifier : AIDSLINE MED/96179307
Parada NA; Cruikshank WW; Danis HL; Ryan TC; Center DM; Department of Medicine, Pulmonary Center, Boston University; School of Medicine, MA 02118, USA.

Abstract: Human interleukin-16, previously known as lymphocyte chemoattractant factor, is a CD4+ T cell competence growth factor initially described as a chemotactic factor for CD4+ cells. The interaction between IL-16 and its receptor CD4 leads to an increase in intracytoplasmic calcium and inositol triphosphate. Because of the association of intracellular shifts in protein kinase C (PKC) enzyme activity with production of these secondary messengers and the participation of PKC in transducing certain receptor-mediated migratory signals, we investigated the role of PKC in the CD4-mediated migratory response by IL-16. Recombinant IL-16 induces rapid translocation of PKC from the cytosol to the membrane in three separate CD4+ cell types: normal blood T cells, SUPT1 cells, and THP1 cells. PKC inhibitors H7, calphostin C, chelerythrine, and bisindolylmaleimide completely block IL-16-induced lymphocyte migration as well as the motile response induced by HIV-1 gp120 and anti-CD4 antibodies. Taken together, these data suggest a role for PKC in CD4-mediated migratory responses.

Keywords: Antibodies, Monoclonal/IMMUNOLOGY/METABOLISM/PHARMACOLOGY Antigens, CD4/IMMUNOLOGY/*METABOLISM/*PHARMACOLOGY Cell Line Cell Movement/*DRUG EFFECTS Cyclic AMP-Dependent Protein Kinases/ANTAGONISTS & INHIB Enzyme Activation Human HIV Envelope Protein gp120/PHARMACOLOGY Lymphokines/METABOLISM/*PHARMACOLOGY Protein Kinase C/ANTAGONISTS & INHIB/*PHYSIOLOGY Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. T-Lymphocytes/DRUG EFFECTS/ENZYMOLOGY/*IMMUNOLOGY JOURNAL ARTICLE
960730
M9670512

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .